Thymosin β4 protects C57BL/6 mice from bleomycin‐induced damage in the lung. (16th January 2013)
- Record Type:
- Journal Article
- Title:
- Thymosin β4 protects C57BL/6 mice from bleomycin‐induced damage in the lung. (16th January 2013)
- Main Title:
- Thymosin β4 protects C57BL/6 mice from bleomycin‐induced damage in the lung
- Authors:
- Conte, Enrico
Genovese, Tiziana
Gili, Elisa
Esposito, Emanuela
Iemmolo, Maria
Fruciano, Mary
Fagone, Evelina
Pistorio, Maria P.
Crimi, Nunzio
Cuzzocrea, Salvatore
Vancheri, Carlo - Abstract:
- <abstract abstract-type="main" id="eci12048-abs-0001"> <title>Abstract</title> <sec id="eci12048-sec-0001" sec-type="section"> <title>Background</title> <p>Thymosin β4 (Tβ4) was recently found at high concentration in the bronchoalveolar lavage fluid (BALF) of scleroderma patients with lung involvement. It has been hypothesized that Tβ4 may exert a cyto‐protective effect during lung injury because lower Tβ4 levels were associated with interstitial lung disease progression. Moreover, Tβ4 treatment prevented profibrotic gene expression in cardiac cells <italic>in vitro</italic> and <italic>in vivo</italic>.</p> </sec> <sec id="eci12048-sec-0002" sec-type="section"> <title>Materials and methods</title> <p>In this study, we explored a putative Tβ4 protective role in lung damage by utilizing a well‐known <italic>in vivo</italic> model of lung fibrosis. C57BL/6 mice were treated with bleomycin (BLEO, 1 mg/kg) in the absence or presence of Tβ4 (6 mg/kg delivered intraperitoneally on the day of BLEO treatment and for two additional doses). After sacrifice 1 week later, measurement of fluid and collagen content in the lung, BALF analysis, myeloperoxidase (MPO) activity assay, lung histology and IHC were performed.</p> </sec> <sec id="eci12048-sec-0003" sec-type="section"> <title>Results</title> <p>Compared with BLEO‐treated mice, BLEO‐treated mice who received Tβ4 did not lose as much weight and had a higher survival rate. Moreover, BLEO‐induced inflammation and lung damage were<abstract abstract-type="main" id="eci12048-abs-0001"> <title>Abstract</title> <sec id="eci12048-sec-0001" sec-type="section"> <title>Background</title> <p>Thymosin β4 (Tβ4) was recently found at high concentration in the bronchoalveolar lavage fluid (BALF) of scleroderma patients with lung involvement. It has been hypothesized that Tβ4 may exert a cyto‐protective effect during lung injury because lower Tβ4 levels were associated with interstitial lung disease progression. Moreover, Tβ4 treatment prevented profibrotic gene expression in cardiac cells <italic>in vitro</italic> and <italic>in vivo</italic>.</p> </sec> <sec id="eci12048-sec-0002" sec-type="section"> <title>Materials and methods</title> <p>In this study, we explored a putative Tβ4 protective role in lung damage by utilizing a well‐known <italic>in vivo</italic> model of lung fibrosis. C57BL/6 mice were treated with bleomycin (BLEO, 1 mg/kg) in the absence or presence of Tβ4 (6 mg/kg delivered intraperitoneally on the day of BLEO treatment and for two additional doses). After sacrifice 1 week later, measurement of fluid and collagen content in the lung, BALF analysis, myeloperoxidase (MPO) activity assay, lung histology and IHC were performed.</p> </sec> <sec id="eci12048-sec-0003" sec-type="section"> <title>Results</title> <p>Compared with BLEO‐treated mice, BLEO‐treated mice who received Tβ4 did not lose as much weight and had a higher survival rate. Moreover, BLEO‐induced inflammation and lung damage were substantially reduced by Tβ4 treatment, as demonstrated by the significant reduction in oedema, total collagen content, lung infiltration by leucocytes, MPO activity in lung homogenates, and histological evidence of the ongoing lung fibrosis. Results of IHC show a strong reactivity for Tβ4 in the lung tissue of Tβ4‐treated mice.</p> </sec> <sec id="eci12048-sec-0004" sec-type="section"> <title>Conclusions</title> <p>This is the first report that shows a Tβ4 protective role in lung toxicity associated with BLEO in a mouse model. Future studies are needed to assess its putative antifibrotic properties.</p> </sec> </abstract> … (more)
- Is Part Of:
- European journal of clinical investigation. Volume 43:Number 3(2013:Mar.)
- Journal:
- European journal of clinical investigation
- Issue:
- Volume 43:Number 3(2013:Mar.)
- Issue Display:
- Volume 43, Issue 3 (2013)
- Year:
- 2013
- Volume:
- 43
- Issue:
- 3
- Issue Sort Value:
- 2013-0043-0003-0000
- Page Start:
- 309
- Page End:
- 315
- Publication Date:
- 2013-01-16
- Subjects:
- Pathology -- Periodicals
Medical research -- Periodicals
616.075 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2362 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/eci.12048 ↗
- Languages:
- English
- ISSNs:
- 0014-2972
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.727100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3383.xml